Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sight SciencesSGHT -1.93%70 3-Year EBITDA Growth Rate is 28.10% as of Jun. 2026. GuruFocus rates SGHT with a GF Score™ of 70/100 and a GF Value™ of $4.63 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 690 Medical Devices & Instruments companies, Sight Sciences ranks better than 75.07% on this metric.
During the past 3 years, the average EBITDA Per Share Growth Rate was 28.10% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 13.10% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 8 years, the highest 3-Year average EBITDA Per Share Growth Rate of Sight Sciences was 28.10% per year. The lowest was -69.70% per year. And the median was -4.00% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Sight Sciences 3-Year EBITDA Growth Rate Related Terms
SGHT vs TMCI, TLSI, SENS: 3-Year EBITDA Growth Rate Comparison
For the Medical Devices subindustry, Sight Sciences's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sight Sciences 3-Year EBITDA Growth Rate vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Sight Sciences's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Sight Sciences's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 28.10% mean?
Sight Sciences (SGHT) has a 3-Year EBITDA Growth Rate of 28.10% as of Jun. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Sight Sciences and its competitors. According to the industry distribution chart, Sight Sciences ranks #172 out of 690 companies in the Medical Devices & Instruments industry, placing it in the top 24.9%.
Is Sight Sciences' 3-Year EBITDA Growth Rate too high?
Sight Sciences' current 3-Year EBITDA Growth Rate is 28.10%. The Medical Devices & Instruments industry median 3-Year EBITDA Growth Rate is 8.20. Sight Sciences' value of 28.10% is 242.7% above this industry median. Based on the distribution chart, Sight Sciences ranks #172 out of 690 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Sight Sciences has a GF Score™ of 70/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Sight Sciences' 3-Year EBITDA Growth Rate compare to TMCI and TLSI?
According to the Medical Devices & Instruments industry distribution chart, Sight Sciences ranks #172 out of 690 companies for 3-Year EBITDA Growth Rate. This places Sight Sciences in the top 25% of its industry — outperforming the majority of peers. The industry median 3-Year EBITDA Growth Rate is 8.20. Sight Sciences' value of 28.10% is 242.7% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Medical Devices & Instruments company?
The median 3-Year EBITDA Growth Rate among Medical Devices & Instruments companies is 8.20, based on 690 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sight Sciences's current 3-Year EBITDA Growth Rate of 28.10% is 242.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Sight Sciences and its competitors. For the Medical Devices & Instruments industry, the median 3-Year EBITDA Growth Rate is 8.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sight Sciences's current 3-Year EBITDA Growth Rate is 28.10%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sight Sciences stock overvalued right now?
Based on GuruFocus' analysis, Sight Sciences (SGHT) is currently considered Significantly Overvalued. The stock's GF Value™ is $4.63, compared to a current price of $8.14 — trading 75.7% above its estimated fair value. The current 3-Year EBITDA Growth Rate is 28.10% and 242.7% above the Medical Devices & Instruments industry median of 8.20. Sight Sciences' overall GF Score™ is 70/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Sight Sciences (SGHT), the current 3-Year EBITDA Growth Rate is 28.10% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sight Sciences (SGHT) Overvalued in 2026?
Based on GuruFocus' analysis, Sight Sciences stock appears to be overvalued.
The current stock price of $8.14 is trading 75.7% above its estimated GF Value™ of $4.63.
GuruFocus considers Sight Sciences to be Significantly Overvalued.
Key valuation signals for SGHT:
3-Year EBITDA Growth Rate: 28.10%
GF Value™: $4.63 vs. price of $8.14 (75.7% above fair value)
Industry Position: 242.7% above the Medical Devices & Instruments median (#172 of 690)
No single metric tells the full story. See the SGHT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sight Sciences Inc is an ophthalmic medical device company focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. The company operates through two segments: Interventional Glaucoma, which generates the majority of revenue and includes the OMNI Surgical System family of products and the SION Surgical Instrument used in minimally invasive glaucoma surgery to reduce intraocular pressure in adult patients with open-angle glaucoma; and Interventional Dry Eye, which includes the TearCare System, an interventional device designed to melt and facilitate the removal of meibomian gland obstructions and restore gland functionality in adult patients with evaporative dry eye disease.
70GF Score
Get the complete analysis for SGHT
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SGHT has been successfully added to your 
